The geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone marrow stromal cells

Pediatric Hematology and Oncology

Volumn 22, Issue 2, 2005, Pages 115-125

  Hawkins, Lindsay M ^a   Narendran, Aru ^a  

^a ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

17 AAG; Bone marrow stroma; Myelodysplastic syndrome; VEGF

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; CYTOKINE; INTERLEUKIN 6; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; STROMA CELL;

BENZOQUINONES; BONE MARROW CELLS; CELL PROLIFERATION; CHILD; CHROMOSOMES, HUMAN, PAIR 8; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA; MYELODYSPLASTIC SYNDROMES; PARACRINE COMMUNICATION; RIFABUTIN; STROMAL CELLS; TRISOMY; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 14644439277     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010590896477     Document Type: Article

References (31)

1. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427-1434.
2. Brynes RK, Swayne D, McCourty A, Dosik GM, Traweek ST, Slovak ML. Detection of trisomy 8 by fluorescence in situ hybridization on bone marrow smears from patients with subtle myelodysplastic changes. Arch Pathol Lab Med. 1994;118:1196-1200.
3. Hasle H, Clausen N, Pedersen B. Bendix-Hansen K. Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genet Cytogenet. 1995;79:79-81.
4. Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol. 2003;31:693-701.
5. Narendran A, Hawkins LM, Ganjavi H, et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol 2004;21:209-221.
6. Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res. 2002;11:119-125.
7. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2001;106:170-176.
8. Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets. 2003;3:297-300.
9. Chavany C, Mimnaugh E, Miller P, et al. p185erbB2 binds to GRP94 in vivo: dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem. 1996;271:4974-4977.
10. Whitesell L, Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol. 1996;10:705-712.
11. Nguyen DM, Desai S, Chen A, Weiser TS, Schrump DS. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg. 2000;70:1853-1860.
12. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002;62:2478-2482.
13. Poulaki V, Mitsiades CS, McMullan C, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocnnol Metab. 2003;88:5392-5398.
14. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor l7-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 2001;61:4003-4009.
15. Kamel-Reid S, Dick JE, Greaves A, et al. Differential kinetics of engraftment and induction of CD10 on human pre-B leukemia cell lines in immune deficient scid mice. Leukemia. 1992;6:8-17.
16. Kumagai M, Manabe A, Pui CH, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest. 1996;97:755-760.
17. List AF, Garewal HS, Sandberg AA. The myelodysplastic syndromes: biology and implications for management. J Clin Oncol. 1990;8:1424-1441.
18. List AF. New approaches to the treatment of myelodysplasia. Oncologist. 2002;7(Suppl 1):39-49.
19. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166.
20. Aguayo A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep. 2004;3:184-191.
21. Wax S, Piecyk M, Maritim B, Anderson P. Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum. 2003;48:541-550.
22. Richter K, Buchner J. Hsp90: chaperoning signal transduction. J Cell Physiol. 2001;188:281-290.
23. Blagosklonny MV. STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon.' Leukemia. 2002;16:570-572.
24. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHlP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA. 2002;99:12847-12852.
25. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000;11:355-360.
26. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425:407-410.
27. George P, Ball P, Cohen P, et al. Cotreatment with 17-allylamino- demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004;64:3645-3652.
28. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17- demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergisticaily induces apoptosis in human leukemia cells. Cancer Res. 2003;63:8420-8427.
29. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res. 2003;9:4483-4493.
30. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002;100:3041-3044.
31. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001;61:1799-1804.